anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The swine is a valuable model for preclinical research and surgical technique training. Induction of Type I diabetes is achieved by total pancreatectomy, therefore these animals may be used in several research studies, including islet transplantation field. Given the lack of information in the literature, the purpose of this work is to describe anatomic aspects of swine pancreas, the total pancreatectomy surgical technique, intra- and postoperative complications and the autopsy results.
MATERIAL AND METHODS: Five hybrid male pigs, 20-35 kg, submitted to total pancreatectomy with duodenum, bile duct, and spleen preservation. Postoperatively, daily clinical assessment and capillary blood glucose collection were performed. At the end of the 30-day period or in the occurrence of serious clinical complications, euthanasia and autopsy were performed.
RESULTS: The average duration of surgery was 128 minutes, without intraoperative deaths or anesthesia induction failures. The median survival was 6.6 days. Postoperative complications were weight loss (3), emesis (2), constipation (2), abdominal distension (2), diarrhea (1), and loss of appetite (1). All animals were euthanized due to serious complications. Two animals presented surgical complications (duodenal necrosis with gastroparesis and internal hernia with intestinal necrosis). The other 3 animals presented serious clinical complications related to exocrine pancreatic insufficiency due to deficiency of pancreatic enzymes. Glycemic values above 200 mg/dL were found on the first postoperative day and above 300 mg/dL on the seventh day in all animals.
CONCLUSION: A model of total pancreatectomy with duodenum, spleen, and bile duct preservation in pigs was established. All animals became diabetic, however, animals without postoperative complications were euthanized due to serious complications related to pancreas exocrine insufficiency.
FIELD: medicine. SUBSTANCE: essence of this invention resides in using already known L-pyroglutamic acid amide as claimed nootropic drug. Though this medicine is already known in the art, its nootropic properties have not been described in literature and it has not been previously used for treating any diseases. L-pyroglutamic acid amide produces no toxic effects when administered in doses up to 12,000 mg/kg. To put it otherwise, this drug is less toxic than pyracetame (8,000 mg/kg). In passive avoidance conventional reaction test, this drug advantages learning ability by 50 % as compared with control figures, whereas pyracetame taken in substantially greater doses encourages leaning ability solely by 20 %. Therapeutic value and range of claimed medicine (2,000) is considerably greater than those of pyracetame (60). Novel drug exhibits nootropic activity when administered perorally and produces protective effect in experiment against amnesia provoked by either electric convulsive shock or administration of L-proline cetyl ether. Dosage in this case is also lower than that of pyracetame. L-pyroglutamic acid amide administered in experiment produces protective effect in case of alcoholic intoxication in dosage smaller than that of pyracetame. EFFECT: highly effective small doses of claimed drug improve learning ability and memory and capable of protecting central nervous system from amnesic effects and alcoholic intoxication; low toxicity is another advantage of this drug which is of certain interest in sphere of psychoneurology and reanimatology. 5 tbl
PURPOSE: A pharmaceutical composition containing a novel peptide which enhances transcription activity of VEGF(Vascular Endothelial Growth Factor) is provided to activate VEGF gene through HIF-1alpha activation and to promote wound healing, skin tissue regeneration, and hair growth. CONSTITUTION: A pharmaceutical composition for wound healing and skin tissue regeneration contains a peptide with a base sequence selected from sequence numbers 1-3. The peptide enhances the expression of HIF-1alpha, VEGF, fibronectin, or collagen. The peptide proliferates VEGF and enhances cell migration. A method for wound healing or skin tissue regeneration comprises a step of administering the pharmaceutical composition to an individual. [Reference numerals] (AA) Gauze; (BB) Existing salve; (CC) Base; (DD) **p<0.01 and ***p<0.001 as compared with base control(base)
A mascara composition comprising, in an aqueous matrix, a styrene/acrylic copolymer ammonium and an acrylate/VA copolymer as a plasticizer. At the concentrations specified herein, the resulting mascara compositions have a variety of useful properties that can be controlled, such as transition temperature, viscosity, drying time, and shrinkage. The compositions of the present invention are hydrophilic. However, after application, the composition dries to a contracted hydrophobic state that retains the curl. The applied compositions resist transfer, smearing, flaking, wetting, oil and sebum making them well suited as 24 hour long-wearing cosmetics. Some preferred embodiments comprise an abnormally high concentration of nylon fibers, which increases the volume and elongation of the lashes.
PURPOSE:To obtain the function-improving agent for motion consciousness and language disorders originated from central nervous system disorders. CONSTITUTION:The function-improving agent for motion, consciousness and language disorders contains an L-norepinephrine precursor, hydroxy-dopa [(-)- threo-3-(3,4-dihydroxyphenyl)L-serine] of the formula, as an active ingredient. The function-improving agent is effective for the improvement of motor paralysis and motor aphasia which are generated during cerebral hemorrhage such as subarachnoid hemorrhage, cerebral infarction or cerebral hemorrhage or after posttraumatic encephalopathia and which are not improved only by physical therapies. The function-improving agent is especially effective to improve the recovery rate. The function-improving agent is effective for the recovery of consciousness and will disorders in cerebral hemorrhage not accompanied with a brainstem disorder. The function-improving agent preferably contains benserazide for enhancing the intracerebral transfer of the hydroxy dopa. The function-improving agent is preferably orally administered at a dose of 2-6mg/ day (the amount of the hydroxy dopa), preferably 4-6mg/day.
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a liver disorder characterized by the ac-cumulation of fat in hepatocytes without alcohol consumption. Mitochondrial dysfunction and endoplasmic reticulum (ER) stress play significant roles in NAFLD pathogenesis. The unfolded protein response in mitochondria (UPRmt) is an adaptive mechanism that aims to restore mitochondrial protein homeostasis and mitigate cellular stress. This study aimed to investigate the effects of ( +)-Lipoic acid (ALA) on UPRmt, inflammation, and oxidative stress in an in vitro model of NAFLD using HepG2 cells treated with palmitic acid and oleic acid to induce steatosis.
RESULTS: Treatment with palmitic and oleic acids increased UPRmt-related proteins HSP90 and HSP60 (heat shock protein), and decreased CLPP (caseinolytic protease P), indicating ER stress activation. ALA treatment at 1 μM and 5 μM restored UPRmt-related protein levels. PA:OA (palmitic acid:oleic acid)-induced ER stress markers IRE1α (Inositol requiring enzyme-1), CHOP (C/EBP Homologous Protein), BIP (Binding Immunoglobulin Protein), and BAX (Bcl-2-associated X protein) were significantly reduced by ALA treatment. ALA also enhanced ER-mediated protein glycosylation and reduced oxidative stress, as evidenced by decreased GPX1 (Glutathione peroxidase 1), GSTP1 (glutathione S-transferase pi 1), and GSR (glutathione-disulfide reductase) expression and increased GSH (Glutathione) levels, and improved cellular senescence as shown by the markers β-galactosidase, γH2Ax and Klotho-beta.
CONCLUSIONS: In conclusion, ALA ameliorated ER stress, oxidative stress, and inflammation in HepG2 cells treated with palmitic and oleic acids, potentially offering therapeutic benefits for NAFLD providing a possible biochemical mechanism underlying ALA beneficial effects.
This is a Phase II study to determine the overall survival for patients with locally advanced NSCLC treated with cetuximab with concurrent thoracic radiotherapy followed by consolidation chemotherapy with paclitaxel/carboplatin/cetuximab. This is a multicenter study including 36 subjects who will be males and females, both greater than 18 years of age. All subjects will initially receive radiation and cetuximab. Radiation will be given once a day (Monday-Friday) for approximately 6-8 weeks. During the course of radiation, cetuximab will be given intravenously once a week. Approximately 4-6 weeks after the last radiation dose, the subjects will be treated with chemotherapy, paclitaxel/carboplatin. Chemotherapy will be given intravenously once every 3 weeks for 3 cycles (1 cycle=3 weeks). Cetuximab intravenous administration will be continued throughout the entire study, once a week through week 26 including during chemotherapy.
The invention relates to a traditional Chinese drug for the treatment of breast diseases. The breast diseases are the common diseases and frequently encountered diseases of females and stubborn for treatment, and the incidence rate is up to 80 percent. In recent years, mastopathy is in the peak time and the canceration rate is relatively high. However, mammary cancer stands the first on the top list of female tumors from the fifth place a few years ago to be the leading cause of the health of women. The traditional Chinese drug is prepared by angelica, safflower, Trichosanthes kirilowii Maxim, forsythia, taraxacum, boswellia carteri, myrrh, cinnamon, Flos Caryophyllata and borneol. In the formula thereof, the angelica and the safflower have the functions for promoting blood circulation, promoting menstrual flow and relieving pains and are monarch drugs in a prescription; the Trichosanthes kirilowii Maxim has the functions for relieving rheumatic pains and removing obstruction in the meridians, and the forsythia and the taraxacum have the functions of clearing away heat and toxic materials, detumescence and eliminating stagnation. The three traditional Chinese drugs are all ministerial drugs; the boswellia carteri and the myrrh with the functions of activating blood circulation and relieving pains as well as the cinnamon with the functions of removing cold and obstruction in the meridians and activating blood circulation to relieve pains are adjuvant drugs; Flos Caryophyllata with the functions of warming channels to dispel cold and borneol with the functions of hot in nature of a drug and running through the body and promoting menstrual flow and relieving pains are messenger drugs. The monarch drugs in a prescription, the ministerial drugs, the adjuvant drugs and the messenger drugs have the efficacies of activating blood circulation and removing obstruction in the meridians as well as promoting qi circulation to relieve pain.
Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA. Overall, the incidence of serious infections in controlled trials was similar in patients receiving BENLYSTA compared with placebo, whereas fatal infections occurred more frequently in patients receiving BENLYSTA [see Adverse Reactions (6.1)].

Consider the risk and benefit before initiating treatment with BENLYSTA in patients with severe or chronic infections. Consider interrupting therapy with BENLYSTA in patients who develop a new infection while receiving it and monitor these patients closely.

Progressive Multifocal Leukoencephalopathy (PML)

Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. Consider the diagnosis of PML in any patient presenting with new-onset or deteriorating neurological signs and symptoms and consult with a neurologist or other appropriate specialist as clinically indicated. In patients with suspected PML, immunosuppressant therapy, including BENLYSTA, must be suspended until PML has been excluded. If PML is confirmed, immunosuppressant therapy, including BENLYSTA, must be discontinued.
PROBLEM TO BE SOLVED: To obtain a hair-treating agent composition capable of improving the retention of dyed color and reducing the discoloration of dyed hair, when the composition is applied to the hair before and/or after a hair-dyeing treatment using a direct dye, by adding an amino acid. SOLUTION: This hair-treating agent composition contains an amino acid, preferably a basic amino acid such as arginine, in an amount of 0.1-10 wt.% based on the total amount of the composition. The pH of the composition is preferably 2.0-6.5. A hair dye used together with the composition is a direct dye, preferably the black 401 and/or the violet 401 as acidic dyes, and is contained in an amount of 0.05-5 wt.%. The form of the composition includes a cream-like form, a lotion-like form, a jell-like form and a form-like form. The composition is applied, for example, by an application method comprising coating hair with the composition before a hair-dyeing treatment, leaving the coated hair at room temperature to 45 deg.C for about 5-30 min, and then washing off the composition.
Malaria caused by Plasmodium falciparum continues to be a global problem with devastating consequences. Pregnancy malaria is associated with low birth weight (LBW), maternal anemia, and gestational hypertension; and both inflammation and the fetal response to infection may contribute to these poor outcomes. Pregnancy malaria (PM) is caused by P. falciparum-infected erythrocytes that bind to the placental receptor chondroitin sulfate A (CSA) and sequester in the placenta, where they cause disease and death for the mother and her offspring. Women become resistant to pregnancy malaria as they acquire antibodies that target surface proteins of placental parasites. Malaria vaccine candidates targeting the parasite s liver stage or blood stage may not protect pregnant women and their unborn children. The primary hypothesis in this study is that antibodies raised in animals against recombinant pregnancy malaria vaccine candidates will have a similar functional activity as naturally acquired antibodies. Up to 2492 malaria-infected pregnant women will be recruited into a cross sectional study that will be conducted in Ouelessebougou and neighboring districts, Mali. Women presenting for antenatal visit at the health centers in Ouelessebougou District will be enrolled. Samples collected from the women will be used in in-vitro assays to assess the functional activity of immunoglobulin G (IgG) raised against pregnancy malaria vaccine candidates as the primary outcome of this study. For our secondary outcomes, we will examine functional activity of naturally acquired antibodies specific to the vaccine candidates. Functional activity by IgG to vaccine candidates will be compared to the activity obtained with control proteins using appropriate statistical methods, including adjustment for possible confounders such as parasite density in the assay, to determine if the candidates elicit the type of immune response observed in naturally exposed population.
Disclosed is a homogeneously pure monocyte chemotactic protein, CAP37, and the entire coding sequences for unprocessed and mature human CAP37 protein. Further, the recombinant production, from nucleic acid coding sequences, of mature CAP37 protein and the mature protein with amino-terminal and/or carboxy-terminal extensions is described. Also disclosed are methods to identify and recombinantly produce bioactive peptides derived from the CAP37 protein coding sequence which are effective chemoattractants of monocytes and/or are capable of binding bacterial lipopolysaccharide. A method of preparing homogeneously pure CAP37 using hydrophobic HPLC is described. Bioactive peptide fragments of CAP37 having chemotactic, antibacterial and/or LPS-binding activity are disclosed. Finally, methods of treating wounds, diseased tissue, such as tumors, and infections are described.
Serving more than 95% of US children ages 5-17, the school environment is a valuable setting to engage students in Physical Activity (PA) through the day, but is limited when physical education programs have insufficient curricular, time, financial and staffing allocations. A growing body of research supports the premise that interventions focused on increasing physical activity in schools may be more successful if supported by evidence that increased PA improves academic achievement, that is the clear priority for limited school time and resources.

The purpose of this study is to examine the impact of a school-based physical activity intervention on fourth and fifth grade elementary students' academic achievement, as measured by standardized test scores. Baseline information about current physical activity practices will be collected. Schools will receive ongoing in-person and virtual training, and schools will be provided physical activity equipment, resources, and teaching aids. Student accelerometer data will allow for monitoring of physical activity levels. This study seeks to address gaps in the literature by studying the efficacy of a well-established intervention that has been shown to impact school physical activities practices, and shows promise of efficacy for improving student education outcomes.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common adverse reactions in adult patients with mildly to moderately active ulcerative proctitis in double-blind, placebo-controlled trials are summarized in the Table 1 below.

In a multicenter, open-label, randomized, parallel group study in 99 patients comparing the Mesalamine Rectal Suppository 1000 mg suppository administered nightly to that of the mesalamine 500 mg suppository twice daily. The most common adverse reactions in both groups were headache (14%), flatulence (5%), abdominal pain (5%), diarrhea (3%), and nausea (3%). Three (3) patients discontinued medication because of an adverse reaction; one of these adverse reactions (headache) was deemed possibly related to study medication. The recommended dosage of Mesalamine Rectal Suppositories is 1000 mg administered rectally once daily at bedtime [see Dosage and Administration (2)].
Fluoxetine hydrochloride is a selective serotonin reuptake inhibitor for oral administration. It is designated (±)-N-methyl-3-phenyl-3-[(α,α,α-trifluoro-p-tolyl)oxy]propylamine hydrochloride and has the molecular formula of C17H18F3NO•HCl. Its molecular weight is 345.79. The structural formula is:

Fluoxetine hydrochloride, USP is a white or almost white powder, very soluble in ethanol and in chloroform, slightly soluble in acetone and practically insoluble in toluene.

Each scored tablet contains fluoxetine hydrochloride, USP equivalent to 60 mg (194 µmol) of fluoxetine. In addition, each scored tablet also contains the following inactive ingredients: colloidal silicon dioxide, corn starch, crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
<P>PROBLEM TO BE SOLVED: To provide a pH adjusting agent having pH buffer ability equal or superior to that of an inorganic phosphate in the neutral to acid region, not affecting taste/flavor, and little in causing the adverse effect of calcium absorption inhibition.  <P>SOLUTION: The pH adjusting agent contains at least one phosphorylated saccharide selected from phosphorylated starch, phosphorylated dextrin, phosphorylated reduced dextrin, phosphorylated reduced oligosaccharide, phosphorylated monosaccharide and their salts, and/or salts thereof, or contains at least one phosphorylated saccharide selected from phosphorylated dextrin and phosphorylated oligosaccharide both obtained by making phosphorylated starch that is obtained by the phosphorylation of starch into a smaller molecule and their salts, and/or salts thereof. There are provided foods, drinks, seasonings, taste improvers, oral hygienic agents, detergents, bathing agents, cosmetics, pharmaceuticals, mineral supplements, mineral absorption enhancers, pastes, admixtures, paints, pigments, feedstuff and fertilizers using the pH adjusting agent. A manufacturing method of coffee drinks is provided, in which heat sterilization treatment is conducted after the above pH adjusting agent is added and the pH is adjusted. The coffee drinks containing the pH adjusting agent are also provided.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Cancer-associated fibroblasts (CAFs) exhibit notable versatility, plasticity, and robustness, actively participating in cancer progression through intricate interactions within the tumor microenvironment (TME). N6-methyladenosine (m6A) modification is the most prevalent modification in eukaryotic mRNA, playing essential roles in mRNA metabolism and various biological processes. Howbeit, the precise involvement of m6A in CAF activation remains enigmatic. In this study, we revealed that the m6A demethylase FTO supports CAF-mediated angiogenesis through activation of EGR1 and VEGFA in conjunctival melanoma (CoM). First, single-cell transcriptome analysis revealed that FTO was specifically upregulated in the CAF population, thereby contributing to the hypo-m6A status in the TME of CoM. Moreover, CAFs of CoM displayed extensive proangiogenic potential, which was largely compromised by FTO inhibition, both in vitro and in vivo. By employing multi-omics analysis, we showed that FTO effectively eliminates the m6A modifications of VEGFA and EGR1. This process subsequently disrupts the YTHDF2-dependent mRNA decay pathway, resulting in increased mRNA stability and upregulated expression of these molecules. Collectively, our findings initially indicate that the upregulation of FTO plays a pivotal role in tumor development by promoting CAF-mediated angiogenesis. Therapeutically, targeting FTO may show promise as a potential antiangiogenic strategy to optimize cancer treatment.
Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Chewing Gum Group are asked to chew gum four times a day for 5 days (15 minutes each time) after surgery in addition to standard cares. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.